Burns J W & Co. Inc. NY Sells 393 Shares of Zoetis Inc. (NYSE:ZTS)

Burns J W & Co. Inc. NY lessened its holdings in Zoetis Inc. (NYSE:ZTS) by 1.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,988 shares of the company’s stock after selling 393 shares during the quarter. Burns J W & Co. Inc. NY’s holdings in Zoetis were worth $5,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in ZTS. Vanguard Group Inc. grew its position in Zoetis by 1.0% during the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after buying an additional 414,605 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares during the period. Bank of New York Mellon Corp grew its position in shares of Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares during the period. Capital Research Global Investors increased its stake in shares of Zoetis by 2.3% during the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after purchasing an additional 90,330 shares during the last quarter. Finally, Clearbridge Investments LLC raised its holdings in shares of Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock worth $527,774,000 after purchasing an additional 166,517 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

ZTS traded down $0.96 during trading on Friday, reaching $190.03. 1,697,760 shares of the company were exchanged, compared to its average volume of 2,576,563. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company’s 50-day moving average is $187.30 and its two-hundred day moving average is $175.45. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market cap of $86.09 billion, a price-to-earnings ratio of 36.61, a P/E/G ratio of 2.95 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.41 earnings per share. Research analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ZTS shares. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus lifted their price objective on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. Finally, Piper Sandler upped their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average price target of $220.38.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.